Alpha-Lipoic Acid Explained Simply
Alpha-lipoic acid is a substance produced by the body that helps in cells with energy production and is offered as a dietary supplement.
1. What Is Alpha-Lipoic Acid?
Alpha-lipoic acid is a sulfur-containing substance. The body itself produces small amounts of it. In cells, it helps convert sugar into energy. It is also offered as a dietary supplement. In some countries, approved medicines are additionally available.
2. Where Is It Found, and What Is It Made From?
Alpha-lipoic acid occurs in small amounts in foods. These include spinach, broccoli, potatoes and yeast. It is also contained in liver and kidney. For dietary supplements and study preparations, it is chemically produced. It usually occurs as a mixture of both enantiomers; only the R form occurs in the body.
3. What Does Alpha-Lipoic Acid Do? What Research Shows
| Area | State of research | Studies |
|---|---|---|
| Oxidative stress (laboratory markers) | several indications | 77 |
| Glucose and fat metabolism | several indications | 74 |
| Nerve damage, especially in diabetes | several indications | 65 |
| Weight and body composition | several indications | 25 |
| Liver | still unclear | 11 |
| Eye and retina | still unclear | 3 |
| Other investigations | well studied, mostly positive | 146 |
Oxidative Stress (Laboratory Markers)
In several review articles, inflammation markers in the blood decreased 93229. Antioxidative capacity also improved in some studies 49526063. Other studies found no difference here 182548505761. These results are laboratory values and not clinical effects. The studies were often small and inconsistent.
Glucose and Fat Metabolism
Several reviews show that alpha-lipoic acid can lower fasting blood glucose 213137 and long-term blood glucose 2131. Two others found no difference in long-term blood glucose 1423. Insulin resistance also improved in several studies 21375664. For cholesterol, there were partly improvements 152433, partly no difference 121416. The studies were heterogeneous and mostly short.
Nerve Damage, Especially in Diabetes
In diabetic nerve damage, alpha-lipoic acid improved symptoms in several reviews 52023262839. Pain also decreased in some studies 34412328. However, two reviews with placebo comparison (sham treatment) found no confirmed difference 1127. Combinations with other agents cannot be attributed to alpha-lipoic acid alone 236710. For other nerve damage, the benefit was unclear.
Weight and Body Composition
Oral alpha-lipoic acid slightly lowered body weight in several reviews and studies 21354043. A review also reports a decrease in fat mass 21. In chronic kidney disease and polycystic ovary syndrome, however, BMI remained unaffected 2425. The findings apply to oral intake.
Liver
In fatty liver, a review found no advantage for liver enzymes 16. A randomized (participants assigned by lot) study also showed no difference in liver enzymes and liver fat 55. After liver transplantation, circulatory problems upon restoring blood flow (post-reperfusion syndrome) occurred less often with alpha-lipoic acid than with placebo 58. The studies are small and short. Overall, there was predominantly no advantage.
Eye and Retina
For the eye, only one randomized controlled study (with a comparison group) is available. After acute optic neuritis, the retinal nerve fiber layer decreased with alpha-lipoic acid as with placebo 59. The study was small and short. Reliable statements about retinal function cannot be derived from it. A case series (description of several individual cases) reports improvements, but only for a mixture with other substances 65.
Other Investigations
In this area, very different endpoints (study target value) were examined, predominantly with oral intake. Several studies found less pain, for example in migraine, burning mouth syndrome and hemorrhoids 283638424446. In men with fertility disorders, sperm motility improved 18196263. Vascular function improved in several studies 174764, blood pressure decreased in a review and two randomized studies 135154. Mood and depression scores improved in two randomized studies 4852.
4. How Was Alpha-Lipoic Acid Taken in the Studies?
In the studies, alpha-lipoic acid was predominantly given orally as a tablet, capsule or dietary supplement. The summaries mostly do not state which form was used. Individual investigations administered alpha-lipoic acid intravenously, especially in diabetic nerve damage. The two mirror-image forms were not examined separately in the studies with a comparison group.
5. Is Alpha-Lipoic Acid Safe? Side Effects in the Studies
The studies predominantly report no serious adverse events and no difference in treatment discontinuations due to side effects 111. Side effects occurred at higher doses; at lower doses, administration was considered safe 26. Case reports describe an insulin autoimmune syndrome after intake, which subsided after discontinuation 30. Findings on laboratory values such as oxidative stress are not clinical effects.
All details with tables and sources: full expert page on Alpha-Lipoic Acid
Frequently Asked Questions
Does Alpha-lipoic acid help with oxidative stress (laboratory markers)? What the studies show
Does Alpha-lipoic acid help with glucose and fat metabolism? What the studies show
Does Alpha-lipoic acid help with nerve damage, especially in diabetes? What the studies show
Does Alpha-lipoic acid help with weight and body composition? What the studies show
Does Alpha-lipoic acid help with liver? What the studies show
Sources
- 1Fogacci F, Rizzo M, Krogager C, Kennedy C, Georges CMG, Knežević T et al. · 2020
- 2Jiang DQ, Li MX, Ma YJ, Wang Y, Wang Y · 2016
- 3Zhao M, Chen JY, Chu YD, Zhu YB, Luo L, Bu SZ · 2018
- 4Abubaker SA, Alonazy AM, Abdulrahman A · 2022
- 5Hsieh RY, Huang IC, Chen C, Sung JY · 2023
- 6Ran GL, Li YP, Lu LC, Lan SH · 2024
- 7Jiang DQ, Xu LC, Jiang LL, Li MX, Wang Y · 2018
- 8
- 9Vajdi M, Mahmoudi-Nezhad M, Farhangi MA · 2023
- 10
- 11Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL · 2024
- 12
- 13Vajdi M, Noshadi N, Hassanizadeh S, Bonyadian A, Seyedhosseini-Ghaheh H, Askari G · 2023
- 14Ebada MA, Fayed N, Fayed L, Alkanj S, Abdelkarim A, Farwati H et al. · 2019
- 15Mahmoudinezhad M, Farhangi MA · 2023
- 16
- 17Jalilpiran Y, Hajishafiee M, Khorshidi M, Rezvani H, Mohammadi-Sartang M, Rahmani J et al. · 2021
- 18Pires IZ, Gobbo MODS, Sudo RYU, Milbradt TL, Marquardt N, Carvalhal GF et al. · 2025
- 19Dong L, Yang F, Li J, Li Y, Yu X, Zhang X · 2022
- 20
- 21Mohammadi S, Ashtary-Larky D, Alaghemand N, Alavi I, Erfanian-Salim M, Pirayvatlou PS et al. · 2026
- 22Saeed TN, Al-Hussainy AF, Sanghvi G, Roopashree R, Kashyap A, Anand DA et al. · 2026
- 23Salinas AV, Caroca TM, Santibáñez FP, González JR, López-Chaparro M, Barahona-Vásquez M et al. · 2026
- 24Rezaei H, Ravankhah M, Ansari M, Alirezaee A, Keshavarzian O, Abdollahi M et al. · 2025
- 25Abu-Zaid A, Baradwan S, Bukhari IA, Alyousef A, Abuzaid M, Saleh SAK et al. · 2024
- 26Das S, Viswanatha GL, Kishore A, Nandakumar K · 2024
- 27Orellana-Donoso M, López-Chaparro M, Barahona-Vásquez M, Santana-Machuca A, Bruna-Mejias A, Nova-Baeza P et al. · 2023
- 28Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G · 2022
- 29Đukić L, Trajković L, Knežević T, Dimitrijević J, Krstić D, Stojanović M · 2022
- 30EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI et al. · 2021
- 31Rahimlou M, Asadi M, Banaei Jahromi N, Mansoori A · 2019
- 32Haghighatdoost F, Hariri M · 2019
- 33Haghighatdoost F, Hariri M · 2019
- 34Amato Nesbit S, Sharma R, Waldfogel JM, Zhang A, Bennett WL, Yeh HC et al. · 2019
- 35Namazi N, Larijani B, Azadbakht L · 2018
- 36Liu YF, Kim Y, Yoo T, Han P, Inman JC · 2018
- 37Akbari M, Ostadmohammadi V, Lankarani KB, Tabrizi R, Kolahdooz F, Khatibi SR et al. · 2018
- 38Kisely S, Forbes M, Sawyer E, Black E, Lalloo R · 2016
- 39Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ · 2012
- 40Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E et al. · 2011
- 41El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA · 2020
- 42Wu C, Yuan P, Qiu X, Liu D, Xu Y, Xiao Y et al. · 2025
- 43Li N, Yan W, Hu X, Huang Y, Wang F, Zhang W et al. · 2017
- 44Šabanović M, Jašić M, Odobašić A, Aleksovska ES, Pavljašević S, Bajraktarević A et al. · 2018
- 45Tutunchi H, Arefhosseini S, Ebrahimi-Mameghani M · 2023
- 46Kelishadi MR, Naeini AA, Khorvash F, Askari G, Heidari Z · 2022
- 47Mohammadi V, Aghababaee SK, Khorvash F, Dehghani S, Askari G · 2025
- 48Rezaei Kelishadi M, Alavi Naeini A, Askari G, Khorvash F, Heidari Z · 2021
- 49Rizkalla BA, Kelany MR, Sabri NA, Shawki MA · 2026
- 50Kolahi S, Mirtaheri E, Pourghasem Gargari B, Khabbazi A, Hajalilou M, Asghari-Jafarabadi M et al. · 2019
- 51Mohammadi V, Khorvash F, Feizi A, Askari G · 2018
- 52
- 53Aslfalah H, Jamilian M, Rafiei F, Khosrowbeygi A · 2019
- 54Mohammadi V, Khalili M, Eghtesadi S, Dehghani S, Jazayeri S, Aghababaee SK et al. · 2015
- 55Hosseinpour-Arjmand S, Amirkhizi F, Ebrahimi-Mameghani M · 2019
- 56Kaviyani N, Keshavarz SA, Abbasi B · 2020
- 57Shaafi S, Ebrahimpour-Koujan S, Khalili M, Shamshirgaran SM, Hashemilar M, Taheraghdam A et al. · 2020
- 58Casciato P, Ambrosi N, Caro F, Vazquez M, Müllen E, Gadano A et al. · 2018
- 59Falardeau J, Fryman A, Wanchu R, Marracci GH, Mass M, Wooliscroft L et al. · 2019
- 60Georgakouli K, Fatouros IG, Fragkos A, Tzatzakis T, Deli CK, Papanikolaou K et al. · 2018
- 61Habibi M, Abbasi B, Fakhari Zavareh Z, Esmaeili V, Shaverdi A, Sadighi Gilani MA et al. · 2022
- 62Abbasi B, Molavi N, Tavalaee M, Abbasi H, Nasr-Esfahani MH · 2020
- 63Haghighian HK, Haidari F, Mohammadi-Asl J, Dadfar M · 2015
- 64Serhiyenko VA, Serhiyenko LM, Sehin VB, Serhiyenko AA · 2021
- 65Abdelkader M, Saleh S, Mokbel T, Abouelkheir H, Abd El Ghafar A · 2019
- 66Mateo Orobia AJ, Benítez Del Castillo JM, Calonge M, Baudouin C, Labetoulle M · 2025
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.